Why Medicare coverage of Wegovy now looks possible

FDA permission for Novo Nordisk to market heart benefits of its obesity drug Wegovy could provide a backdoor way to win Medicare coverage.

March 14, 2024 Check out STAT+

Sponsored By

Steffen Trumpf/picture alliance/Getty Images STAT+ | Medicare couldn't cover Wegovy for weight loss. But now that it's also a heart drug, the door is open FDA permission for Novo Nordisk to market heart benefits of its obesity drug Wegovy could provide a backdoor way to win Medicare coverage. By Rachel Cohrs Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan If the drug, obeldesivir, is shown to be effective in people and is approved, it would be the first oral treatment for any type of Ebola. By Helen Branswell STAT+ | EPA restricts cancer-causing chemical used to sterilize medical devices Ethylene oxide used to sterilize devices that can't be exposed to steam, but long-term exposure linked to cancer. Vaporized hydrogen peroxide deemed safer. By Lizzy Lawrence Mariam Zuhaib/AP Senators press HHS secretary on Change HealthCare cyberattack fallout Senate Finance Chairman Ron Wyden pressed HHS Secretary Xavier Becerra to institute cybersecurity requirements for hospitals and insurers. By Sarah Owermohle STAT+ | AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal The deal for the French firm, worth up to $1 billion, comes as the British pharma giant expands its efforts in rare diseases. By Andrew Joseph STAT+ | Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K. The cost-effectiveness agency known as NICE said it wanted more information about Casgevy's effectivenss and durability. By Andrew Joseph Adobe Opinion: Prescription for resilience: Health care needs financial sector-inspired regulation U.S. health care's critical technology infrastructure needs to be bolstered by strong regulation that stress-tests against cyberattacks. By Jonathan Slotkin and David Vawdrey

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser